Literature DB >> 19565672

Immunoregulatory effects of indoleamine 2, 3-dioxygenase in transplantation.

Lining Jia1, Puxun Tian, Chenguang Ding.   

Abstract

Indoleamine 2, 3-dioxygenase (IDO) is an intracellular hemeprotein enzyme which catalyses the essential amino acid tryptophan. Accumulating evidence has demonstrated that tryptophan depletion and its toxic metabolites expression in tissue microenvironment can suppress local allogeneic T cell proliferation and activation. Ever since the discovery that IDO was involved in the maintenance of fetal-maternal tolerance, numerous studies have confirmed that IDO is a potent regulator of immune cell function. Importantly, IDO+dendritic cells (DCs) might interact with regulatory T cells (Tregs) to form an immunomodulatory network to promote immune tolerance induction. Moreover, it has been reported that overexpression of IDO in transplanted organs can prolong allograft survival, suggesting a possible peripheral tolerogenic pathway with important implications in transplantation. However, the underlying mechanism for the beneficial effects of IDO in transplantation remains unclear. In this review, we attempt to summarize our current understandings about IDO as a mediator of immunity in transplantation and provide an overview of IDO as a new paradigm in transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19565672     DOI: 10.1016/j.trim.2009.01.004

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  8 in total

1.  Immune biomarker panel monitoring utilizing IDO enzyme activity and CD4 ATP levels: prediction of acute rejection vs. viral replication events.

Authors:  Vikas R Dharnidharka; Sushil Gupta; Eihab Al Khasawneh; Allah Haafiz; Jonathan J Shuster; Douglas W Theriaque; Amir H Shahlaee; Timothy J Garrett
Journal:  Pediatr Transplant       Date:  2011-02-24

2.  Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia.

Authors:  Chun-Yan Wang; Yan Shi; Ya-Nan Min; Xiao-Juan Zhu; Cheng-Shan Guo; Jun Peng; Xiao-Yuan Dong; Ping Qin; Jian-Zhi Sun; Ming Hou
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

3.  Verification of association of elevated serum IDO enzyme activity with acute rejection and low CD4-ATP levels with infection.

Authors:  Vikas R Dharnidharka; Eihab Al Khasawneh; Sushil Gupta; Jonathan J Shuster; Douglas W Theriaque; Amir H Shahlaee; Timothy J Garrett
Journal:  Transplantation       Date:  2013-09       Impact factor: 4.939

4.  Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance.

Authors:  Taba Kheradmand; Shusen Wang; Jane Bryant; James J Tasch; Nadine Lerret; Kathryn L Pothoven; Josetta L Houlihan; Stephen D Miller; Zheng J Zhang; Xunrong Luo
Journal:  J Immunol       Date:  2012-06-13       Impact factor: 5.422

5.  Human cytomegalovirus IE1 protein elicits a type II interferon-like host cell response that depends on activated STAT1 but not interferon-γ.

Authors:  Theresa Knoblach; Benedikt Grandel; Jana Seiler; Michael Nevels; Christina Paulus
Journal:  PLoS Pathog       Date:  2011-04-14       Impact factor: 6.823

6.  Shikonin Prolongs Allograft Survival via Induction of CD4+FoxP3+ Regulatory T Cells.

Authors:  Qiaohuang Zeng; Feifei Qiu; Yuchao Chen; Cuihua Liu; Huazhen Liu; Chun-Ling Liang; Qunfang Zhang; Zhenhua Dai
Journal:  Front Immunol       Date:  2019-04-01       Impact factor: 7.561

7.  Protective Role of Kynurenine 3-Monooxygenase in Allograft Rejection and Tubular Injury in Kidney Transplantation.

Authors:  Randi Lassiter; Todd D Merchen; Xuexiu Fang; Youli Wang
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

Review 8.  The applications of bone marrow-derived stem cells to induce tolerance and chimerism in organ transplantation.

Authors:  M Ebrahimi; N Aghdami
Journal:  Int J Organ Transplant Med       Date:  2010
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.